- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Carbon Composite.
Displaying page 1 of 2.
EudraCT Number: 2020-001322-54 | Sponsor Protocol Number: CS/2018/6632 | Start Date*: 2020-06-15 | ||||||||||||||||||||||||||
Sponsor Name:University Hospitals Bristol and Weston NHS Foundation Trust | ||||||||||||||||||||||||||||
Full Title: Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial | ||||||||||||||||||||||||||||
Medical condition: Brain injury during open heart valve surgery | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000371-26 | Sponsor Protocol Number: DFI12712 | Start Date*: 2015-08-14 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of olipudase alfa in Patients With... | |||||||||||||
Medical condition: Patients with acid sphingomyelinase deficiency (Niemann-Pick Type B disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) PT (Completed) ES (Ongoing) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002500-91 | Sponsor Protocol Number: RPC01-3001 | Start Date*: 2015-10-12 | |||||||||||
Sponsor Name:Celgene International II Sàrl (CIS II) | |||||||||||||
Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001233-89 | Sponsor Protocol Number: SGI-110-04 | Start Date*: 2015-05-15 | |||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for I... | |||||||||||||
Medical condition: Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) BE (Completed) HU (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) CZ (Completed) AT (Completed) ES (Completed) PL (Completed) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000381-11 | Sponsor Protocol Number: CCMK389X2201 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar... | |||||||||||||
Medical condition: Chronic pulmonary sarcoidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004990-13 | Sponsor Protocol Number: KRM-307 | Start Date*: 2007-10-17 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Corporation [...] | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease includin... | |||||||||||||
Medical condition: Moderate to Severe Chronic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004655-20 | Sponsor Protocol Number: LIGHT | Start Date*: 2019-05-30 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL) | |||||||||||||
Medical condition: CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000697-22 | Sponsor Protocol Number: FGCL-3019-095 | Start Date*: 2020-11-02 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005623-27 | Sponsor Protocol Number: RM-131-009 | Start Date*: 2015-04-08 | |||||||||||
Sponsor Name:Rhythm Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropa... | |||||||||||||
Medical condition: Vomiting symptoms in patient with moderate to severe diabetic gastroparesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004989-17 | Sponsor Protocol Number: KRM-306 | Start Date*: 2007-10-17 | |||||||||||
Sponsor Name:Mitsubishi Tanabe Pharma Corporation [...] | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease | |||||||||||||
Medical condition: Moderate to Severe Chronic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005461-14 | Sponsor Protocol Number: LD-VenEx | Start Date*: 2022-04-20 |
Sponsor Name:Righospitalet | ||
Full Title: The Nordic AML Group – LD-VenEx: PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (INCLUDING EXPLORATORY EVALUATION OF EX VIVO DRUG SENS... | ||
Medical condition: Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) DK (Ongoing) FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004405-34 | Sponsor Protocol Number: GS-US-231-0101 | Start Date*: 2010-09-13 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmon... | |||||||||||||
Medical condition: Idiopathic pulmonary fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005206-10 | Sponsor Protocol Number: PR200-104 | Start Date*: 2022-04-12 | |||||||||||
Sponsor Name:Prometheus Biosciences, Inc. | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD). | |||||||||||||
Medical condition: Systemic sclerosis associated with interstitial lung disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) HU (Ongoing) NO (Completed) NL (Ongoing) IT (Ongoing) PL (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003124-44 | Sponsor Protocol Number: DKMS-14-01 | Start Date*: 2015-01-15 | ||||||||||||||||
Sponsor Name:DKMS gemeinnützige GmbH | ||||||||||||||||||
Full Title: Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML | ||||||||||||||||||
Medical condition: | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002966-29 | Sponsor Protocol Number: CCTL019H2301 | Start Date*: 2019-03-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA) | |||||||||||||
Medical condition: adult patients with aggressive B-cell NHL after failure of rituximab and anthracycline containing first line immunochemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) NL (Ongoing) BE (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003633-42 | Sponsor Protocol Number: RBHIPF004 | Start Date*: 2013-10-18 | |||||||||||||||||||||||||||||||
Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease | |||||||||||||||||||||||||||||||||
Medical condition: A diagnosis of connective tissue disease associated interstitial lung disease, based on internationally accepted criteria, in one of the following categories: o Systemic sclerosis o Idiopathic inte... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004772-18 | Sponsor Protocol Number: ASTX727-07 | Start Date*: 2022-05-30 | |||||||||||
Sponsor Name:Astex Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia (AML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001323-12 | Sponsor Protocol Number: PEVOLAM | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: A randomized phase III, multicentre, open label clinical trial comparing azacitidine plus pevonedistat versus azacitidine in Older/Unfit patients with newly diagnosed acute myeloid leukemia who are... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001790-41 | Sponsor Protocol Number: 2215-CL-0201 | Start Date*: 2016-06-07 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukem... | |||||||||||||
Medical condition: Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) DE (Restarted) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Completed) PL (Completed) HU (Prematurely Ended) GR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003855-40 | Sponsor Protocol Number: MOR208C115 | Start Date*: 2022-03-09 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref... | |||||||||||||
Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) IT (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.